POP BIO awarded $2.84M Phase II SBIR for seasonal influenza vaccine development
BUFFALO, NY, UNITED STATES, November 26, 2024 /EINPresswire.com/ -- POP Biotechnologies Inc. (POP BIO) received a $2.84M Phase II SBIR under award number 1R44AI181479-01, supported by the National Institute of Allergies and Infectious Disease ( …